SEC 13F Intelligence

Tri Locum Partners LP / XENE

Tri Locum Partners LP’s Xenon Pharmaceuticals Inc Position

Does Tri Locum Partners LP own Xenon Pharmaceuticals Inc (XENE)? Not currently — the last reported position was 366.1K shares worth $15M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$15M
Q3 2025
Shares
366.1K
% of Portfolio
+3.38%
Quarters Held
12
position exited

Position History XENE

Reported value by quarter
Q3 ’21: $4MQ3 ’21Q4 ’21: $782,000Q2 ’22: $5MQ2 ’22Q3 ’22: $5MQ4 ’22: $4MQ4 ’22Q1 ’23: $8MQ2 ’23: $932,509Q2 ’23Q3 ’23: $6MQ4 ’23: $10MQ4 ’23Q1 ’24: $9MQ2 ’24: $4MQ2 ’24Q3 ’25: $15Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025366.1K$15M+3.38%
Q2 2024102.0K$4M+1.01%
Q1 2024207.5K$9M+3.10%
Q4 2023225.6K$10M+4.75%
Q3 2023171.8K$6M+1.88%
Q2 202324.2K$932,509+0.35%
Q1 2023221.7K$8M+2.42%
Q4 202293.4K$4M+1.49%
Q3 2022134.3K$5M+1.33%
Q2 2022166.4K$5M+2.07%
Q4 202125.0K$782,000+0.31%
Q3 2021264.1K$4M+1.60%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Tri Locum Partners LP’s full portfolio or all institutional holders of XENE.